Stock Details
4519.T is Chugai Pharmaceutical Co., Ltd.'s stock. Stock exchange Tokyo (Currency JPY). Average price in 50 days is 3,469.18๏ฟฅ. Average daily volumn in 3 months 2.14M. Market cap 5.52T



Stock symbol : 4519.T. Exchange : Tokyo. Currency : JPY
Lastest price : 3,358.00๏ฟฅ. Total volume : 1.73M. Market state POSTPOST
Click reload if you want to check the lastest price on market!!!

Chugai Pharmaceutical Co., Ltd. (4519.T)
Last Price
3,358.00๏ฟฅ
Change
-34.00
Volume
1.73M

Previous Close3,392.00
Open3,370.00
Day Range3,349.00-3,391.00
Bid3,349.00 x N/A
Ask3,358.00 x N/A
Volume1.73M
Average Volume2.14M
Market Cap5.52T
Beta0.54
52 Week Range3,191.00-4,320.00
Trailing P/E14.90
Foward P/E17.40
Dividend (Yield %)2.24%
Ex-Dividend Date2022-12-29



Financial Details


According to Chugai Pharmaceutical Co., Ltd.'s financial reports the company's revenue in 2021 were 999.76B an increase( +27.1%) over the years 2020 revenue that were of 786.95B. In 2021 the company's total earnings were 303B while total earnings in 2020 were 214.73B( +41.59%).


Loading ...



Organization

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; osteoporosis, including Actemra, Edirol, and Bonviva; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyr... oidism; and other diseases comprise Hemlibra, CellCept, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

Market Cap:
5.52T
Revenue:
999.76B
Total Assets:
1.54T
Total Cash:
267.75B


News about "Chugai Pharmaceutical Co., Ltd."

Chugai Pharmaceutical Co., Ltd.

Source from : Nikkei Asia - 1 month ago

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and ...See details»


Thrombocytopenia Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 27+ Companies Working in the Domain

Source from : YAHOO!Finance - 1 days ago

The prevalence of thrombocytopenia has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of Thrombocytopenia and the growing ...See details»


Area woman convicted in $65M pharmaceutical fraud scheme

Source from : The Oakland Press - 9 days ago

A 23-year-old Dearborn woman was convicted Jan. 13 for her role in a scheme that stole $65 million from various pharmaceutical co-pay assistance programs. Suzan Berroโ€™s trial took six days ...See details»


Chugai Mining Co Ltd (1491)

Source from : Investing - 1 month ago

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...See details»


Abbott Under Federal Investigation Over Baby Formulaโ€”Hereโ€™s How The Pharmaceutical Giant Got Here

Source from : Forbes - 10 days ago

The Department of Justice opened a criminal investigation on Friday into an Abbott Laboratories plant in Michigan over unsanitary workplace conditions in its production of baby formulaโ€”the ...See details»


Lotte completes purchase of Bristol Myers Squibbโ€™s pharmaceutical plant in East Syracuse

Source from : syracuse.com - 26 days ago

Syracuse, N.Y. -- South Korean conglomerate Lotte has completed its $160 million purchase of Bristol Myers Squibbโ€™s pharmaceutical plant in East Syracuse. As part of the transaction, the newly ...See details»


Twitter Files: Drugmakers pushed for censorship of generic vaccine advocacy

Source from : Washington Examiner - 14 days ago

When asked how to monitor these alleged campaigns related to the requests offered by a pharmaceutical company, a Twitter spokesperson pulled together a collection of tweets that could be alleged ...See details»


Global Viscosupplementation Market Report 2022: Sector to Reach $6.27 Billion by 2028 at a 9.1% CAGR

Source from : Benzinga.com - 9 days ago

The "Global Viscosupplementation Market, Size, Global Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis" report has been added to ...See details»


Chugai Ro Co Ltd (1964)

Source from : Investing - 26 days ago

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...See details»


global-viscosupplementation-market-size-global-forecast-2023-2028-industry-trends-growth-impact-of-inflation-opportunity-company-analysis-image

Global Viscosupplementation Market, Size, Global Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis

Source from : Yahoo Finance - 13 days ago

Global Viscosupplementation Market is expected to reach US$ 6.27 Billion by 2028 According to the research. Patients with osteoarthritis have a minimally invasive therapeutic option called ...See details»


fda-approves-roches-actemra-for-the-treatment-of-covid-19-in-hospitalised-adults-image

FDA approves Rocheโ€™s Actemra for the treatment of COVID-19 in hospitalised adults

Source from : Yahoo Style UK - 1 month ago

Actemra is the first FDA-approved monoclonal antibody to treat COVID-19 Since the beginning of the pandemic, more than one million people hospitalised with COVID-19 have been treated with Actemra ...See details»


Lilly To Invest $450M For Pharmaceutical Manufacturing Site

Source from : Business Facilities - 5 days ago

Since 2020, Lilly has committed roughly $4 billion to new pharmaceutical manufacturing facilities in North Carolina, including $1.7 billion for the development and expansion of its site at ...See details»


Novan secures $5M through license deal with Japanese pharma

Source from : The Business Journals - 26 days ago

Novan (Nasdaq: NOVN) in late December announced that its fully consolidated subsidiary EPI Health has entered an exclusive license agreement with Sato Pharmaceutical Co., through which the latter ...See details»


KSPHF Kissei Pharmaceutical Co., Ltd.

Source from : Seeking Alpha - 6 days ago

The chart has 1 X axis displaying Time. Data ranges from 2022-01-25 00:00:00 to 2023-01-25 15:30:16. The chart has 1 Y axis displaying symbol price. Data ranges from 17.04 to 21.1.See details»